Biotech is back. But continued investor caution, the rise of China and fast-moving AI are changing the sector’s contours.
In Nature Biotechnology’s latest feature, Biotech’s Coming of Age, the industry’s leading investors reflect on the forces reshaping biotech, from capital efficiency and AI-driven innovation to the growing influence of China in drug development. Forbion’s Sander Slootweg and Nanna Lüneborg share their perspectives on how the sector is evolving and what it will take for the next generation of biotech companies to succeed in an increasingly global and competitive landscape.
Access the article on the Nature website here.
